Author:
Bauer Andrea,Dickel Heinrich,Jakob Thilo,Kleinheinz Andreas,Lippert Undine,Metz Martin,Schliemann Sibylle,Schwichtenberg Uwe,Staubach Petra,Valesky Eva,Wagner Nicola,Wedi Bettina,Maurer Marcus
Abstract
Abstract
Background
Chronic urticaria (CU) is a common disease which represents a considerable burden for many patients. The current urticaria guideline describes the evidence-based diagnosis and treatment of CU. In addition, however, questions often arise in everyday practice that are not addressed by the guideline.
Methods
In May 2020, a digital meeting with German urticaria experts was held, in which practical aspects of CU treatment were discussed and supporting aids for everyday clinical treatment formulated. The resulting advice in this document focus on practical questions and the available literature and experiences of the participants.
Results
The diagnosis of CU can be made in a short time by means of a thorough anamnesis, a physical examination, and a basic laboratory chemical diagnosis. For this purpose, practical recommendations for everyday practice are given in this paper. An extended diagnosis is only indicated in a few cases and should always be carried out in parallel with an effective therapy. In general, CU should always be treated in the same way, regardless of whether wheals, angioedema or both occur. Symptomatic therapy should be carried out according to the treatment steps recommended by the guidelines. This publication provides practical advice on issues in everyday practice, such as the procedure in the current coronavirus disease 2019 (COVID-19) pandemic, the cardiac risk under higher dosed H1 antihistamines, the self-administration of omalizumab as well as vaccination under omalizumab therapy. In addition to treatment recommendations, topics such as documentation in the practice and family planning with urticaria will be discussed.
Discussion
These supporting treatment recommendations serve as an addendum to the current CU guideline and provide support in dealing with CU patients in everyday practice. The aim is to ensure that patients suffering from CU achieve complete freedom of symptoms with the help of an optimal therapy.
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Maurer M, Abuzakouk M, Bérard F, Canonica W, Oude Elberink H, Giménez-Arnau A, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72:2005–16.
2. Maurer M, Staubach P, Raap U, Richter-Huhn G, Baier-Ebert M, Chapman-Rothe N. ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real-life clinical practice. Br J Dermatol. 2016;174:892–4.
3. Mann C, Dreher M, Weeß HG, Staubach P. Sleep disturbance in patients with urticaria and atopic dermatitis: an underestimated burden. Acta Derm Venereol. 2020;100:adv73.
4. Maurer M, Raap U, Staubach P, Richter-Huhn G, Bauer A, Oppel EM, et al. Antihistamine-resistant chronic spontaneous urticaria: 1‑year data from the AWARE study. Clin Exp Allergy. 2019;49:655–62.
5. Maurer M, Raap U, Staubach P, Richter-Huhn G, Baeumer D, Chapman-Rothe N, editors. Real-world evidence from the AWARE study in Germany highlights the need for greater awareness of guideline recommendations for the treatment of patients with H1-antihistamine-refractory chronic spontaneous urticaria. 50th DDG-Tagung; Berlin. 2019.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献